Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: The preclinical pharmacology of the high affinity anti-IL-6R Nanobody® ALX-0061 supports its clinical development in rheumatoid arthritis

Fig. 1

Development process of ALX-0061. After immunization of a llama with recombinant hIL-6R, a Nanobody phage display library was generated and screened for anti-IL-6R lead candidates. Optimization of the selected lead candidate consisted of humanization, yielding a Nanobody domain with more than 90 % homology to the human germline consensus sequence in the framework regions, and affinity maturation. Formatting of the selected lead anti-IL-6R domain to the HSA binding domain resulted in ALX-0061. After manufacturing in Pichia pastoris, ALX-0061 was tested in vitro and in vivo. hIL-6R: human interleukin-6 receptor; HLE: half-life extension; HSA: human serum albumin; sIL-6R: soluble IL-6R; VHH: heavy-chain-only antibodies

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us